Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts
Source: SeekingAlpha
2025-11-13 22:42:16 ET
More on Vaxart
- Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
- Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow
- Seeking Alpha’s Quant Rating on Vaxart
- Historical earnings data for Vaxart
- Financial information for Vaxart
Read the full article on Seeking Alpha
For further details see:
Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts
Vaxart Inc.
NASDAQ: VXRT
VXRT Trading
-28.75% G/L:
$0.32 Last:
24,017,526 Volume:
$0.412 Open:
VXRT Latest News
February 18, 2026 08:00:00 am
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
January 15, 2026 08:00:00 am
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
January 08, 2026 04:01:00 pm
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
November 13, 2025 04:05:00 pm
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
VXRT Stock Data
$141,641,208
233,347,888
0.84%
5
16957900%
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
